ERBB2 and breast carcinoma: In a previous report from our laboratory, Giordano A et al. [32] revealed that 76.5% of M1 patients with HER2+ breast cancer had circulating tumor cells with epithelial-to-mesenchymal (EMT) characteristics that expressed the transcription factor Twist1.